Fixed-Duration Mosunetuzumab Elicits Durable Responses in R/R Follicular Lymphoma

June 27, 2023Kristi RosaFixed-duration treatment with single-agent mosunetuzumab resulted in a high complete response rate by end of treatment in patients with relapsed or refractory follicular lympho

Oncology October 15,2023

Fixed-Duration Mosunetuzumab Elicits Durable Responses in R/R Follicular Lymphoma

June 27, 2023Kristi RosaFixed-duration treatment with single-agent mosunetuzumab resulted in a high complete response rate by end of treatment in patients with relapsed or refractory follicular lympho

Oncology October 15,2023

Lutetium Lu 177 Vipivotide Tetraxetan Provides HRQOL Benefit, Reduces Skeletal Events in mCRPC

July 9, 2023Kyle DohertyThe addition of lutetium Lu 177 vipivotide tetraxetan to standard-of-care treatment delayed time to worsening of health-related quality of life and skeletal events compared wit

Oncology October 15,2023

Lutetium Lu 177 Vipivotide Tetraxetan Provides HRQOL Benefit, Reduces Skeletal Events in mCRPC

July 9, 2023Kyle DohertyThe addition of lutetium Lu 177 vipivotide tetraxetan to standard-of-care treatment delayed time to worsening of health-related quality of life and skeletal events compared wit

Oncology October 15,2023

ICI-Treated Synchronous mRCC Is Associated With Negative Survival Outcomes

July 17, 2023Ashling WahnerPatients with synchronous metastatic renal cell carcinoma who received first-line immunotherapy had worse survival outcomes compared with those with metachronous metastatic

Oncology October 15,2023

ICI-Treated Synchronous mRCC Is Associated With Negative Survival Outcomes

July 17, 2023Ashling WahnerPatients with synchronous metastatic renal cell carcinoma who received first-line immunotherapy had worse survival outcomes compared with those with metachronous metastatic

Oncology October 15,2023

Adjuvant Nivolumab Receives CHMP Recommendation for Completely Resected Stage IIB/C Melanoma

July 21, 2023Chris RyanThe European Medicines Agency’s Committee for Medicinal Products for Human Use has recommended approval of nivolumab monotherapy for the adjuvant treatment of patients at least

Oncology October 15,2023

Adjuvant Nivolumab Receives CHMP Recommendation for Completely Resected Stage IIB/C Melanoma

July 21, 2023Chris RyanThe European Medicines Agency’s Committee for Medicinal Products for Human Use has recommended approval of nivolumab monotherapy for the adjuvant treatment of patients at least

Oncology October 15,2023

Oncolytic Virus Enables the Immune System to Attack Tumors

by Shana SpindlerOne of the most important findings in cancer research in the past two decades is that tumors can create force field-like protection against the immune system. A new study has identifi

Oncology October 15,2023

Oncolytic Virus Enables the Immune System to Attack Tumors

by Shana SpindlerOne of the most important findings in cancer research in the past two decades is that tumors can create force field-like protection against the immune system. A new study has identifi

Oncology October 15,2023

Is AI Ready to Play a Leading Role in Colorectal Cancer Screening?

by Sharon ReynoldsArtificial intelligence, or AI, is suddenly everywhere. From ChatGPT to automated customer service "representatives,” the ability of computers to perform increasingly complicate

Oncology October 15,2023

Is AI Ready to Play a Leading Role in Colorectal Cancer Screening?

by Sharon ReynoldsArtificial intelligence, or AI, is suddenly everywhere. From ChatGPT to automated customer service "representatives,” the ability of computers to perform increasingly complicate

Oncology October 15,2023

Can Artificial Intelligence–Driven Chatbots Correctly Answer Questions about Cancer?

by Edward WinsteadArtificial intelligence (AI) technologies have become part of everyday life for many people, helping with mundane tasks such as shopping online and using social media. But can AI-dri

Oncology October 15,2023

Can Artificial Intelligence–Driven Chatbots Correctly Answer Questions about Cancer?

by Edward WinsteadArtificial intelligence (AI) technologies have become part of everyday life for many people, helping with mundane tasks such as shopping online and using social media. But can AI-dri

Oncology October 15,2023

BLACK HAIR: TIPS FOR EVERYDAY CARE

Unique in appearance and structure, Black people's hair is especially fragile and prone to injury and damage. More than half of African American women will cite thinning hair or hair loss as their

Dermatology October 15,2023

BLACK HAIR: TIPS FOR EVERYDAY CARE

Unique in appearance and structure, Black people's hair is especially fragile and prone to injury and damage. More than half of African American women will cite thinning hair or hair loss as their

Dermatology October 15,2023

Stem Cell Sources, Types, and Uses in Research

ByDr. Surat P, Ph.D.Reviewed byMichael Greenwood, M.Sc.Stem cells are undifferentiated cells that are capable of self-renewal or differentiation into a specialized cell. They exist within

Stem cells October 15,2023

Stem Cell Sources, Types, and Uses in Research

ByDr. Surat P, Ph.D.Reviewed byMichael Greenwood, M.Sc.Stem cells are undifferentiated cells that are capable of self-renewal or differentiation into a specialized cell. They exist within

Stem cells October 15,2023

he Biology, Structure, and Function of Hair

ByHeather L. Brannon, MDUpdated on November 09, 2022Medically reviewed bySusan Bard, MD窗体顶端Print窗体底端Hair is much more complicated than it looks. You can feel it at the ro

Dermatology October 15,2023

he Biology, Structure, and Function of Hair

ByHeather L. Brannon, MDUpdated on November 09, 2022Medically reviewed bySusan Bard, MD窗体顶端Print窗体底端Hair is much more complicated than it looks. You can feel it at the ro

Dermatology October 15,2023